drugset / Trial / NCT01349868

PT005 MDI Dose Ranging Versus Foradil Aerolizer Study

NCT01349868

Phase 2 Completed 50 enrolled Pearl Therapeutics, Inc.
RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of inhaled PT005 MDI compared to placebo and Foradil Aerolizer in patients with moderate to severe chronic obstructive pulmonary disease (COPD).

Timeline

Start
2011-05
Primary completion
2011-07
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Formoterol Other / unclassified 12 ug
Comparator Formoterol Other / unclassified 24 ug
Subject PT005 Unknown Inhaled